DoctorKristyn Whitmore

Postdoctoral Research Fellow

Menzies Institute for Medical Research

  • Postdoctoral Research Fellow
    Menzies Institute for Medical Research

RESEARCH SUMMARy

Kristyn's work sits at the intersection of nursing, cardiovascular imaging, and preventive medicine. Her key research themes include:

  • Cardiovascular disease prevention, particularly in at-risk populations
  • Patient engagement and behavior change, especially through visualisation of disease (e.g., coronary artery calcium imaging)
  • Medication adherence and lifestyle modification
  • Heart failure management and readmission reduction strategies

Her research often explores how nurse-led interventions and innovative communication strategies can improve patient outcomes.

 

Kristyns work highlights the expanding role of nurses in research leadership and clinical innovation, particularly in chronic disease prevention. Her studies contribute to a growing body of evidence that personalised, visually driven communication can meaningfully change patient behaviour and improve long-term cardiovascular outcomes.

FUNDED PROJECTS

  • GRANT
    Cardio-Diabetic AI-guided Multi-disciplinary disease management program (CD-AIM)
    1 Jun 2026 - 31 May 2031
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Ridge A,
    • Radford J,
    • Wright L
    Project Total: $2,489,786; Could a screening protocol for subclinical LV dysfunction facilitate the selection of patients for a risk-based intervention, and thereby reduce incident HF? The goal of the Cardio-Diabetic AI-Informed disease Management program (CD-AIM) is to reduce the disability and morbidity that would otherwise arise from people with T2DM developing HF, and to preserve functional capacity and quality of life. The objectives are a) to screen asymptomatic individuals with T2DM and without established cardiovascular disease for SBHF with Artificial Intelligence (AI)-guided ECG and echocardiography, b) to undertake a multidisciplinary intervention with cardio-protective strategies, delivered by the study team (Research Nurses and Exercise Physiologists) to delay or prevent their progression to overt HF. Funded by: Medical Research Future Fund - Grant - Preventative and Public Health Research ($2,489,786); University of Tasmania.
  • GRANT
    PERCEIVE-Outreach: A scalable, risk-based model for managing persistent cardiovascular impact in Long Covid
    1 Jun 2026 - 31 May 2030
    People funded by this grant:
    • Huynh Q,
    • Marwick T,
    • Howden E,
    • Radford J,
    • Carrington M
    Project Total: $2,999,687; Despite starting as a respiratory infection by SARS-CoV-2, cardiac injury is commonly reported in COVID-19. Myocardial damage (inflammation and fibrosis), shortness of breath, and chronic fatigue are reported in most recovered patients after 2-3 months, and ongoing cardiac disability is likely a complication in Post-Acute Sequelae of COVID-19 (PASC, commonly known as Long COVID). This research aims to determine key factors that impact hospital admission and death in PASC. These findings will be used to develop a novel screening tool to identify those patients with a high risk of adverse outcomes and a world-first risk-guided healthcare program to effectively manage these risks in people with PASC. This research will include two study samples: A linked dataset provided by Department of Health includes all 7.5 million patients who tested either positive or negative with COVID-19 in Victoria during 2019-22. We will define PASC as monthly occurrence of direct healthcare costs for at least two out of three months after the initial COVID-19 infection to identify people with more severe PASC. This large dataset offers an opportunity to comprehensively investigate the burden of COVID-19. This will be complemented by our ongoing prospective cohort of 979 older Australians recruited from community, with 8-year follow-up (2015-23). This is the world-first paired data BEFORE and AFTER COVID-19 infection with excellent levels of data granularity to enable examination of most key factors of PASC prognosis. The development of a novel risk-guided healthcare program for PASC from our project will result in a reduction in adverse events, hospital admissions, costs, and improved quality of life. This will directly benefit not only millions of patients, but also our health system and clinicians and healthcare providers. It will maximise any investment return in the intervention, an outcome that will be particularly appreciated by healthcare providers with resource constraints. Funded by: Medical Research Future Fund - Grant - Emerging Priorities and Consumer Driven ($2,999,687); University of Tasmania.
  • GRANT
    Aortic Stenosis Screening Using aRtificial intelligence to acquire and interpret Echocardiograms (ASSURE-Echo)
    1 Aug 2025 - 31 Jul 2028
    People funded by this grant:
    • Marwick T,
    • Wright L,
    • Ouyang D,
    • Seidel B,
    • MacIntyre P
    Project Total: $304,920; Degenerative heart valve disease especially its most common serious manifestation, aortic stenosis will increase as the population ages. Recent work from our group has shown that unrecognised, clinically significant valve disease is present in 5% of the population. Because valve diseases are now treatable with minimally-invasive procedures, undiagnosed disease is a cause of preventable death and disability. Echocardiography is the cornerstone diagnostic test in cardiology, and the first step towards appropriate treatment of heart valve disease. Unfortunately, not everyone has the same access to echocardiography our previous work has documented differences in testing across different postcodes, even after correction for age. People living in Rural and Remote Australia (RRA) including but not restricted to the Aboriginal community have the lowest access. Limited access to diagnostic testing is an important contributor to late diagnosis of valve disease. This problem needs urgent remedy because it leads to unnecessary death and disability. Conventional echocardiography requires equipment, a sonographer, and an expert reader. Ultrasound equipment is now inexpensive and widely available, and this proposal will address the other requirements by using AI to both guide non-expert acquisition of echocardiography and provide recognition of aortic stenosis. Both acquisition and recognition components have been developed but this implementation science study will for the first time evaluate the feasibility of a community-based AI screening process for aortic stenosis. Lessons from this study will inform future strategies for the use of AI to improve access to echocardiography in rural and remote Australia. Funded by: Hospitals Contribution Fund Research Foundation - HCF - Hospitals Contribution Fund - Translational Research Grants ($304,926); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Cardio-Diabetic AI-guided Multi-disciplinary disease management program (CD-AIM)
    1 Jan 2025 - 31 Dec 2027
    People funded by this grant:
    • Marwick T,
    • Whitmore K
    Project Total: $350,000; The goal of the Cardio-Diabetic AI-Informed disease Management program (CD-AIM) seeks to reduce the disability and morbidity that would otherwise arise from progression of people with Type 2 Diabetes Mellitus (T2DM) to Heart Failure (HF), and preserve functional capacity and quality of life. The objectives are a) to screen asymptomatic individuals with T2DM and without established cardiovascular disease for Stage B Heart Failure (SBHF) with Artificial Intelligence (AI)-guided ECG and echocardiography, b) to undertake a multidisciplinary intervention with cardio-protective strategies, delivered by a national home-care provider (Amplar Health) to delay or prevent their progression to overt HF. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council; Baker Heart and Diabetes Institute; University of Tasmania.
  • GRANT
    Reducing Cognitive impairment by management of Heart Failure as a Modifiable Risk Factor: Cog-HF
    Baker Heart and Diabetes Institute1 Jan 2024 - 31 Dec 2026
    People funded by this grant:
    • Marwick T,
    • Whitmore K
    Project Total: $340,483; Heart failure and dementia are common and serious problems in the community. Dementia and heart failure frequently co-exist due to shared disease processes and pathological mechanisms. Cognitive impairment – an important sign of dementia – is highly prevalent (>50%) in heart failure. The presence of one may lead to and/or worsen the other. This bidirectional relationship between dementia and heart failure acts as a vicious cycle that increases the burden of both diseases. We have successfully developed a disease management program for heart failure that are shown to reduce repeated hospital admission and mortality. These benefits appeared to be greater among patients with cognitive impairment who have higher risks of adverse outcomes. In this study, we aim to determine if these benefits among patients with cognitive impairment are due to an improvement in cognitive function. RCT to standard care versus an intensive disease management program that focuses on control of the body’s fluid volume, expedited treatment, self-care education and a novel exercise program delivered remotely via a smartphone or tablet application Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($340,483); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Persistent cardiovascular effects of COVID-19 viral infection trial (PERCEIVE-RCT substudy): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
    1 Jan 2022 - 31 Dec 2025
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Schultz M
    Project Total: $533,322; There is some evidence that COVID-19 infection may lead to a risk of heart muscle damage. If this process is left unchecked, it might lead to heart failure, especially as individuals grow older and develop other risks for heart failure. Some cardiac imaging methods have allowed the early detection of cardiac problems before the patient develops heart failure. The study is aimed to identify cardiac complications of COVID-19 and find exercise and medical treatments that will improve these complications. Funded by: Baker Heart and Diabetes Institute ($533,324); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Risk-guided Disease managEment plan to prevEnt heart failure in patients treated with previous cheMotherapy (REDEEM)
    1 Jan 2022 - 31 Dec 2025
    People funded by this grant:
    • Marwick T,
    • Sharman J,
    • Whitmore K,
    • Schultz M
    Project Total: $339,163; The study aims to identify cardiac complications of cancer treatment (chemotherapy) and find exercise and medical treatment that will improve these complications. Some cancer treatments lead to a risk of heart muscle damage. If this process is left unchecked, it can sometimes cause heart failure, especially as patients grow older and develop other risks for heart failure. In this project an ultrasound of the heart (echocardiogram) will be taken in order to measure cardiac status. We are trying to establish whether information from simple tests of the heart could guide treatment to protect patients from developing heart failure. Funded by: Baker Heart and Diabetes Institute ($339,163); University of Tasmania.
  • GRANT
    Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF) A Multicentre, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Pat
    1 Jan 2021 - 31 Dec 2024
    People funded by this grant:
    • Nelson M,
    • Schultz M,
    • Whitmore K
    Project Total: $400,138; To demonstrate that AT-001 compared with placebo decreases the worsening of performance on a cardiopulmonary exercise test (CPET) in patients with Diabetic Cardiomyopathy (DbCM) / Stage B Heart Failure (SBHF) To evaluate the efficacy of AT-001 compared with placebo in preventing progression from SBHF to Stage C Heart Failure (SCHF) defined by the occurrence of one of the following events: o Cardiovascular (CV) death o Hospitalization for heart failure (HF) o Urgent HF visit o New diagnosis of HF Funded by: Medpace Australia Pty Ltd - Clinical Trial ($400,138); University of Tasmania.
  • GRANT
    Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring (EDCAD-PMS)
    1 Jan 2021 - 31 Dec 2023
    People funded by this grant:
    • Marwick T,
    • Whitmore K,
    • Sharman J
    Project Total: $149,300; The research will assess whether genetic (polygenic?) risk scores can improve patient selection for more advanced screening tests, such as coronary imaging or angiograms?, and risk factor management such as elevated cholesterol Main aims for this study are to identify whether: * Polygenetic risk score (PRS) and metabolic risk score can predict the presence of coronary calcium * Knowledge of the PRS result is better or worse than knowledge of the CT scan result in guiding people to reduce their risk (by changing lifestyle and taking medications) Funded by: Baker Heart and Diabetes Institute - Clinical Trial ($149,300); University of Tasmania.
  • GRANT
    Risk-guided strategy for reducing readmission for Acute Decompensated Heart Failure (RiskHELP)
    1 Nov 2019 - 30 Jun 2022
    People funded by this grant:
    • Marwick T,
    • Sharman J,
    • Whitmore K,
    • Dwyer N,
    • Izzettin O
    Project Total: $107,400; A prospective RCT with 320 HF randomised patients admitted with Acute Decompensated Heart Failure (ADHF) confirmed by diagnosis from RHH. Eligible patients (based on study inclusion exclusion criteria), identified by applying the TAS-Help (Study based at Menzies) algorithm as being at high risk for hospital readmission and/or death, will be randomised into two groups of 160 patients each arm. The control arm will receive usual care while the intervention arm will receive DMP-Plus. Patients with ADHF will be screened for a period of 24 months or until targeted sample size is met. Funded by: Medical Research Future Fund - Grant - Keeping Australians Out of Hospital; Baker Heart and Diabetes Institute; University of Tasmania.